Home / Market News / $ABT
benzinga Corporate Catalyst Impact 55/100 ● neutral

Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120

Oct 7, 2026, 12:06 PM UTC · Primary ticker $ABT

Barclays has initiated coverage on Abbott Laboratories with an 'Overweight' rating and set a price target of $120. This analyst coverage indicates a positive outlook from Barclays on ABT's future performance, potentially influencing investor sentiment and the stock's short-term trading activity.

Barclays analyst Matt Miksic initiated coverage on Abbott Laboratories (ABT) with an 'Overweight' rating and a $120 price target. This event is significant as new analyst coverage, especially with a positive rating, can often lead to increased investor interest and a short-term bump in the stock price. It signals that a major financial institution sees upside potential in ABT. For traders, this presents a potential short-term buying opportunity, while long-term investors might view it as validation of their existing holdings. The key risk is that the market may have already priced in such expectations, or other macroeconomic factors could overshadow this positive news.

$ABT positive New 'Overweight' rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.